<DOC>
	<DOCNO>NCT00072579</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor , sargramostim , may increase number immune cell find bone marrow peripheral blood may bring complete remission patient chronic phase chronic myelogenous leukemia . PURPOSE : This phase II trial study sargramostim see well work treat patient chronic phase chronic myelogenous leukemia complete cytogenetic remission initial treatment .</brief_summary>
	<brief_title>Sargramostim Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not Complete Cytogenetic Remission Following Initial Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy safety sargramostim ( GM-CSF ) cytogenetic examination bone marrow patient chronic phase chronic myelogenous leukemia complete cytogenetic remission initial therapy . OUTLINE : Patients receive sargramostim ( GM-CSF ) subcutaneously daily 3 month absence disease progression unacceptable toxicity . Patients achieve response receive GM-CSF additional 3 month . Patients fail achieve partial response well second course GM-CSF remove study . Patients achieve partial response first second course GM-CSF continue receive GM-CSF additional 9 month . Patients re-evaluated . Patients achieve complete cytologic response 9 month receive GM-CSF 3 time weekly absence disease progression unacceptable toxicity . Patients follow every 2 week . PROJECTED ACCRUAL : A total 9-24 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic phase chronic myelogenous leukemia ( CML ) Presence ( 9 ; 22 ) ( q34 ; q11 ) least 20 cell examined metaphase cytogenetic examination bone marrow Complete hematologic remission prior therapy* see 2 separate blood count analysis , define follow : WBC great 10,000/mm^3 AND platelet count great 450,000/mm^3 Disappearance sign symptom disease , include palpable splenomegaly Normal differential count ( i.e. , absence blast , promyelocytes , myelocyte , metamyelocytes ) NOTE : *Continuation therapy lead complete hematologic remission require study participation Persistent cytogenetic disease despite 12 month prior imatinib mesylate therapy , may include trial doseescalation OR intolerant imatinib mesylate dose great 400 mg/day Not complete cytogenetic remission within 30 day study entry Persistent Philadelphia chromosome bone marrow exam PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 6 month Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective contraception No uncontrolled active infective No serious medical psychiatric illness would prevent give informed consent limit survival le 6 month No malignancy remission except curatively treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Prior sargramostim ( GMCSF ) allow Prior interferon alfa CML allow No prior stem cell transplantation Concurrent interferon alfa* CML allow NOTE : *No dose increase study participation Chemotherapy At least 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery At least 4 week since prior surgery Other Prior imatinib mesylate CML allow No concurrent medication CML Concurrent imatinib mesylate* CML allow NOTE : *No dose increase study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>